Emergence and Spread of Carbapenem-resistant Acinetobacter Baumannii International Clones II and III in Lima, Peru
Overview
Authors
Affiliations
Carbapenem-resistant Acinetobacter baumannii is the top-ranked pathogen in the World Health Organization priority list of antibiotic-resistant bacteria. It emerged as a global pathogen due to the successful expansion of a few epidemic lineages, or international clones (ICs), producing acquired class D carbapenemases (OXA-type). During the past decade, however, reports regarding IC-I isolates in Latin America are scarce and are non-existent for IC-II and IC-III isolates. This study evaluates the molecular mechanisms of carbapenem resistance and the epidemiology of 80 non-duplicate clinical samples of A. baumannii collected from February 2014 through April 2016 at two tertiary care hospitals in Lima. Almost all isolates were carbapenem-resistant (97.5%), and susceptibility only remained high for colistin (95%). Pulsed-field gel electrophoresis showed two main clusters spread between both hospitals: cluster D containing 51 isolates (63.8%) associated with sequence type 2 (ST2) and carrying OXA-72, and cluster F containing 13 isolates (16.3%) associated with ST79 and also carrying OXA-72. ST2 and ST79 were endemic in at least one of the hospitals. ST1 and ST3 OXA-23-producing isolates were also identified. They accounted for sporadic hospital isolates. Interestingly, two isolates carried the novel OXA-253 variant of OXA-143 together with an upstream novel insertion sequence (ISAba47). While the predominant A. baumannii lineages in Latin America are linked to ST79, ST25, ST15, and ST1 producing OXA-23 enzymes, we report the emergence of highly resistant ST2 (IC-II) isolates in Peru producing OXA-72 and the first identification of ST3 isolates (IC-III) in Latin America, both considered a serious threat to public health worldwide.
Beig M, Parvizi E, Navidifar T, Bostanghadiri N, Mofid M, Golab N PLoS One. 2024; 19(12):e0311124.
PMID: 39680587 PMC: 11649148. DOI: 10.1371/journal.pone.0311124.
He Z, Huang Y, Li W, Zhang H, Cao R, Ali M Antimicrob Agents Chemother. 2024; 69(1):e0126224.
PMID: 39641569 PMC: 11784083. DOI: 10.1128/aac.01262-24.
Mohamed R, Moustafa N, Mahmoud F, Elsaadawy Y, Abdel Aziz H, Gaber S BMC Microbiol. 2024; 24(1):362.
PMID: 39306657 PMC: 11415996. DOI: 10.1186/s12866-024-03482-3.
Kang H, Kim K, Kim G, Lee D, Kim Y, Choi E Front Cell Infect Microbiol. 2024; 14:1410997.
PMID: 39027135 PMC: 11254764. DOI: 10.3389/fcimb.2024.1410997.
Jiang L, Yin D, Song P, Tang C, Liu X, Hu F Eur J Clin Microbiol Infect Dis. 2024; 43(9):1711-1719.
PMID: 38970691 DOI: 10.1007/s10096-024-04889-6.